Description |
Apixaban is a highly selective, reversible inhibitor of Factor Xa with Ki of 0.08 nM and 0.17 nM in human and rabbit, respectively. |
---|---|
IC50 & Target |
IC50: 0.08 nM (Human Factor Xa), 0.17 nM (Rabbit Factor Xa) |
In Vitro |
Apixaban exhibits a high degree of potency, selectivity, and efficacy on Factor Xa with Ki of 0.08 nM and 0.17 nM for Human Factor Xa and Rabbit Factor Xa, respectively[1]. In vitro, Apixaban prolongs the clotting times of normal human plasma with the concentrations (EC2x) of 3.6 μM, 0.37 μM, 7.4 μM, and 0.4 μM, which are required respectively to double the prothrombin time (PT), modified prothrombin time (mPT), activated partial thromboplastin time (APTT) and HepTest. Besides, Apixaban shows the highest potency in human and rabbit plasma, but less potency in rat and dog plasma in both the PT and APTT assays[2]. |
In Vivo |
Apixaban shows the excellent pharmacokinetics with very low clearance (Cl: 0.02 L/kg/h), and low volume of distribution (Vdss: 0.2 L/kg) in the dogs. Besides, Apixaban also exhibits a moderate half-life (T1/2: 5.8 hours) and good oral bioavailability (F: 58%)[1]. In the arteriovenous-shunt thrombosis (AVST), venous thrombosis (VT) and electrically mediated carotid arterial thrombosis (ECAT) rabbit models, Apixaban produces dose-dependent antithrombotic effects with EC50 of 270 nM, 110 nM and 70 nM, respectively[2]. Apixaban significantly inhibits factor Xa activity with IC50 of 0.22 μM in rabbit ex vivo[3]. In chimpanzee, Apixaban also shows small volume of distribution (Vdss: 0.17 L/kg), low systemic clearance (Cl: 0.018 L/kg/h), and good oral bioavailability (F: 59%)[4]. |
Clinical Trial |
View MoreCollapse
|
References |
|
Preparing Stock Solutions |
Please refer to the solubility information to select the appropriate solvent.
|
||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Kinase Assay
[2] |
Purified FXa is obtained after activation with Russell’s viper venom followed by affinity chromatography. The resulting FXa is > 95% pure as judged by sodium dodecylsulfate polyacrylamide gel electrophoresis. The substrate affinity values for FXa, expressed as the Michaelis-Menten-Henri constant (Km), for human, rabbit, rat and dog FXa are determined using the chromogenic substrate S-2765, and are 36, 60, 240 and 70 μM, respectively. The substrate hydrolysis is monitored by measuring absorbance at 405 nm at 25°C for up to 30 min using a SpectraMax 384 Plus plate reader and SoftMax. FXa activity for each substrate and inhibitor concentration pair is determined in duplicate. The Ki values are calculated by non-linear least-squares fitting of the steady-state substrate hydrolysis rates to the equation for competitive inhibition (Equation 1) using GRAFIT, where v equals reactions velocity in OD min−1, Vmax equals maxiumum reaction velocity, S equals substrate concentration, and I equals inhibitor concentration. MCE has not independently confirmed the accuracy of these methods. They are for reference only. |
||||||||||||||||
Animal Administration
[2] |
Apixaban is formulated in vehicle (10%N,N-dimethylacetamide; 30% 1,2-propanediol; 60% water). Briefly, male New Zealand White rabbits are anesthetized with ketamine (50 mg/kg i.m.) and xylazine (10 mg/kg i.m.), and their femoral artery, jugular vein and femoral vein are catheterized. These anesthetics are supplemented as needed. Thrombosis is induced by an arteriovenous (AV)-shunt device containing a silk thread. Blood flowed from the femoral artery via the AV shunt into the opposite femoral vein for 40 min. The shunt is then disconnected and the silk thread covered with thrombus is weighed. As apixaban has an oral bioavailability of < 5%="" in="" rabbits="" (unpublished="" result),="" it="" is="" administered="" intravenously="" for="" in="" vivo="" studies.="" to="" achieve="" a="" stable="" plasma="" level="" with="" minimum="" experimental="" variability,="" apixaban,="" fondaparinux="" or="" vehicle="" is="" given="" by="" a="" continuous="" intravenous="" infusion="" 1="" h="" prior="" to="" shunt="" placement.="" the="" infusion="" is="" continued="" throughout="" the="" experiment.="" warfarin="" or="" vehicle="" is="" dosed="" orally="" once="" daily="" for="" 4="" days.="" on="" the="" fourth="" day="" after="" the="" last="" oral="" dose="" of="" warfarin="" or="" vehicle,="" rabbits="" are="" anesthetized="" 1.5="" h="" later,="" and="" the="" treatment="" effect="" is="" evaluated="" about="" 2="" h="" postdose.="" arterial="" blood="" samples="" for="" the="" determination="" of="" clotting="" times="" or="" plasma="" levels="" are="" collected="" 20="" min="" after="" shunt="" placement.="" plasma="" levels="" of="" apixaban="" are="" measured="" by="" a="" specific="" and="" sensitive="" liquid="" chromatographic="" mass="" spectrometry="" method="" (lc/ms/ms).="" in="" rabbits="" treated="" with="" apixaban,="" fondaparinux="" or="" warfarin,="" the="" antithrombotic="" effects="" of="" these="" agents="" are="" expressed="" as="" percentage="" inhibition="" of="" thrombus="" formation="" based="" on="" the="" treated="" vs.="" the="" corresponding="" mean="" vehicle.="" the="">50 value (dose that produced 50% inhibition of thrombus formation) is determined as described below. The apixaban group treatment consists of vehicle (10%N,N-dimethylacetamide; 30% 1,2-propanediol; 60% water) (n=4), and apixaban (mg/kg/h) at 0.03 (n=7), 0.1 (n=7), 0.3 (n=7), 1 (n=7), and 3 (n=3). The fondaparinux group treatment consists of vehicle (saline) (n=6), and fondaparinux (mg/kg/h1) at 0.01 (n=5), 0.03 (n=5), 0.1 (n=5), 0.3 (n=5), and 1 (n=5). The warfarin group treatment consists of vehicle (water) (n=6), and warfarin (mg/kg/day) at 0.1 (n=6), 0.3 (n=6), 1 (n=6), and 3 (n=6). MCE has not independently confirmed the accuracy of these methods. They are for reference only. |
||||||||||||||||
References |
|
Molecular Weight |
459.5 |
||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Formula |
C₂₅H₂₅N₅O₄ |
||||||||||||
CAS No. |
503612-47-3 |
||||||||||||
Storage |
|
||||||||||||
Shipping | Room temperature in continental US; may vary elsewhere |
||||||||||||
Solvent & Solubility |
DMSO: 14.25 mg/mL; H2O:< 0.1="">
* "<1 mg/ml"="" means="" slightly="" soluble="" or="" insoluble.="" "≥"="" means="" soluble,="" but="" saturation="">1> |
Purity: 99.97%
COA (94 KB) RP-HPLC (137 KB)
Handling Instructions (1252 KB)-
[1]. Pinto DJ, et al. Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blo
[2]. Wong PC, et al. Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies. J Thromb Haemost. 2008 May;6(5):820-9.
[3]. Zhang D, et al. Metabolism, pharmacokinetics and pharmacodynamics of the factor Xa inhibitor apixaban in rabbits. J Thromb Thrombolysis. 2010 Jan;29(1):70-80.
[4]. He K, et al. Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor. Eur J Drug Metab Pharmacokinet. 2011 Sep;36(3):129-39.
ebiomall.com
>
>
>
>
>
>
>
>
>
>
>
>
westblot蛋白免疫印迹实验跑小分子蛋白(15kd)条带一直是波浪状,有人说是胶的问题,可同时跑了36kd蛋白,条带是直的,有人说是要恒流跑,电压不要太大,我的转膜条件是50v,50min,请教各位大神指点,万分感谢!!!
如题,之前没做过药代,老师给了一个600+Da的五肽,想测下药代动参数,看文献推荐上述两种方法,但是不知道选哪种更好,lcms前处理会不会影响小肽。
求助各位前辈,我最近在合成的化合物水溶性很好,非常好,以至于可以随便溶解在水里,它的六氟磷酸盐也可以随意溶解在水里(大于50uM),细胞成像实验显示它根本进不去细胞,求问有没有啥方法包裹一下让它进去?我搜了一下文献,感觉多数是把脂溶性特别好的东西包裹一下弄进去的,也许是搜索姿势不对没找到我需要的答案,**点拨啊!!!
求助各位大神,现在想购买小分子数据库,求大神推荐。
我知道的免费的数据库有zinc
求推荐哪家公司或者研究所的小分子数据库可以购买,十分感谢!!!!!!
有机的是有机化合物的简称,它指的是含碳化合物.
但是,有四大类常见物质一般不作为有机物处理:
1、碳的氧化物,如CO和CO2.
2、碳酸及其盐,如CaCO3.
3、金属碳化物,如CaC2.
4、拟卤素及其化合物,如(CN)2与KSCN.
水的化学式为H2O,它不含有碳元素,故不是有机物.
但若所描述的水不是化学意义的水,而是自然界存在的天然水,那么,水中会溶有一定量的有机物.
暂无品牌问答